← All candidates
Two insider buys in the last year — $1.2K in all.
20 filings on record.
BOLTBolt Biotherapeutics, Inc.
NasdaqCM · Healthcare · $7.61M
$3.95
+5.90% · Sep 11
Two insider buys in the last year — $1.2K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys◆ 1 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what BOLT ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$7.61M
Float
1.7M
87% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
1.6
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
President, CEO and CFO
Quinn William P.
Bought $686.50 on Jun 6 — 125 sh @ $5.49, held direct, 5.7% of their stake.
0 of 1 position beat the S&P
Senior VP, Finance and PAO
Nemec Sarah
Bought $686.50 on Jun 6 — 125 sh @ $5.49, held direct, 13% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
2 more transactions on Pro →Context
Wall St
$41.00 avg target
+938.0% vs today · 2 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Coverage
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue EstimatesZacks · 08-11Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue EstimatesZacks · 05-12Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue EstimatesZacks · 03-12Bolt Biotherapeutics Inc.: Q4 Earnings SnapshotAssociated Press Finance · 03-12
The file stays open
20 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice